Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.24.2
Condensed Consolidated Statements of Cash Flows (Unaudited)
$ in Thousands
3 Months Ended
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Operating activities    
Net loss $ (121,290) $ (9,955)
Adjustments to reconcile net loss used in operating activities:    
Depreciation and amortization 34 33
Stock-based compensation 629 855
Acquired in-process research and development 27,538 0
Excess of warrant fair value over private placement proceeds 79,276 0
Transaction costs paid pursuant to private placement 7,013 0
Transaction costs payable upon exercise of warrants issued in private placement 1,734 0
Change in fair value of derivative liability 120 180
Accretion of debt discount 0 350
Deferred taxes 7 8
Changes in assets and liabilities:    
Other receivables 101 1,062
Inventory, net 0 1
Prepaid expenses and other assets (154) (337)
Lease incentive 158 0
Accounts payable 470 2,683
Deferred revenue 0 22
Accrued expenses and other liabilities (1,652) (4,941)
Lease liability, net (186) (13)
Net cash used in operating activities (6,202) (10,052)
Investing activities    
Cash assumed from Almata Transaction 356 0
Leasehold improvements 0 (158)
Disposal of property and equipment 0 25
Net cash provided by (used in) investing activities 356 (133)
Financing activities    
Proceeds from private placement investment, gross 115,625 0
Transaction costs paid pursuant to private placement (7,013) 0
Proceeds from issuance of common stock and pre-funded warrants in underwritten public offering, net 0 13,748
Net cash provided by financing activities 108,612 13,748
Increase in cash, cash equivalents and restricted cash 102,766 3,563
Cash, cash equivalents, and restricted cash at beginning of period 7,546 13,318
Cash, cash equivalents, and restricted cash at end of period 110,312 16,881
Supplemental disclosures of cash flow information    
Cash paid for interest 0 704
Supplemental disclosures of non-cash activities    
Issuance of common stock and Series C Preferred Stock pursuant to Almata Transaction 12,727 0
Cash and cash equivalents 110,177 16,687
Restricted cash, current 4 63
Restricted cash, non-current 131 131
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total $ 110,312 $ 16,881